<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5916">
  <stage>Registered</stage>
  <submitdate>3/06/2016</submitdate>
  <approvaldate>3/06/2016</approvaldate>
  <nctid>NCT02793349</nctid>
  <trial_identification>
    <studytitle>The ABSORB Bioresorbable Scaffold Below the Knee Study</studytitle>
    <scientifictitle>ABSORB BTK Study: A Prospective, Multi-center, Controlled Clinical Evaluation of the Use of a Bioresorbable Drug Eluting Stent (Absorb, Abbott Vascular) in the Arterial Vasculature Below the Knee</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>HREC 15/051</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Ischemia</healthcondition>
    <healthcondition>Peripheral Arterial Disease</healthcondition>
    <healthcondition>Arterial Occlusive Diseases</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Absorb Bioresorbable Vascular Scaffold

Experimental: Bioresorbable Vascular Scaffold - Absorb Bioresorbable Vascular Scaffold


Treatment: devices: Absorb Bioresorbable Vascular Scaffold
Absorb Bioresorbable Vascular Scaffold

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Angiographic patency - Freedom from angiographic binary in-scaffold restenosis (&gt;50% stenosis)</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Technical success - Technical success defined as the ability to cross and dilate the lesion to achieve residual angiographic stenosis no greater than 30% and residual stenosis less than 50% by duplex ultrasound (US) imaging.</outcome>
      <timepoint>Procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Haemodynamic primary, assisted primary and secondary patency - Haemodynamic primary, assisted primary and secondary patency as assessed by ultrasound</outcome>
      <timepoint>1 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Haemodynamic primary, assisted primary and secondary patency - Haemodynamic primary, assisted primary and secondary patency as assessed by ultrasound</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Haemodynamic primary, assisted primary and secondary patency - Haemodynamic primary, assisted primary and secondary patency as assessed by ultrasound</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Haemodynamic primary, assisted primary and secondary patency - Haemodynamic primary, assisted primary and secondary patency as assessed by ultrasound</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Haemodynamic primary, assisted primary and secondary patency - Haemodynamic primary, assisted primary and secondary patency as assessed by ultrasound</outcome>
      <timepoint>36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Limb salvage rate (LSR) - Limb salvage defined as 1 minus major amputation rate (major amputation is defined as at or above ankle, as opposed to minor amputation being at or below metatarsus preserving functionality of foot)</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target lesion revascularization (TLR) - Target lesion revascularization (TLR) is defined as a repeat intervention to maintain or re-establish patency within the region of the treated arterial vessel plus 5 mm proximal and distal to the treated lesion edge</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rutherford Category - Clinical success defined as an improvement of Rutherford classification of one class or more as compared to the pre-procedure Rutherford classification</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse clinical events - Clinical events defined as fatal, life-threatening, or judged to be severe by the investigator; resulted in persistent or significant disability; necessitated surgical or percutaneous intervention; or required prolonged hospitalization</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Stenotic (&gt; 50%) or occlusive atherosclerotic disease of the distal popliteal or
             infrapopliteal arteries

          -  A maximum of two focal target lesions in one or more distal popliteal or
             infrapopliteal vessels

          -  Length of lesion is maximally 55 mm, allowing maximally 2 stents to be implanted

          -  Reference vessel diameter should be 2.5 mm-4 mm

          -  Symptomatic critical limb ischemia (Rutherford 3, 4, 5)

          -  Subject is able to take at least one type of thienopyridine (e.g. clopidogrel) and
             acetylsalicylic acid

          -  The patient must be &gt; 18 years of age

          -  Life-expectancy of more than 12 months

          -  The patient has no child bearing potential or negative serum pregnancy test within 7
             days of the index procedure

          -  The patient must be willing and able to return to the appropriate follow-up times for
             the duration of the study

          -  The patient must provide written patient informed consent that is approved by the
             ethics committee</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Patient refusing treatment

          -  The reference segment diameter is not suitable for available stent design.

          -  Unsuccessfully treated (&gt;30% residual stenosis) proximal inflow limiting arterial
             stenosis

          -  Untreatable lesion located at the distal outflow arteries

          -  More than two infrapopliteal lesions in the same limb

          -  Previously implanted stent(s) or PTA at the same lesion site

          -  Lesion location requiring kissing stent procedure

          -  Lesion lies within or adjacent to an aneurysm

          -  Inflow-limiting arterial lesions left untreated

          -  The patient has a known allergy to heparin, Aspirin or other
             anticoagulant/anti-platelet therapies or a bleeding diatheses or is unable, or
             unwilling, to tolerate such therapies.

          -  The patient takes Phenprocoumon (Marcumar).

          -  The patient has a history of prior life-threatening contrast media reaction.

          -  The patient is currently enrolled in another investigational device or drug trial.

          -  The patient is currently breast-feeding, pregnant or intends to become pregnant.

          -  The patient is mentally ill or retarded.

          -  Subject has received a heart transplant or any other organ transplant or is on a
             waiting list for any organ transplant

          -  Subject is receiving or scheduled to receive anticancer therapy for malignancy within
             30 days prior to or after the procedure

          -  Subject is receiving immunosuppression therapy, or has known serious immunosuppressive
             disease (e.g., human immunodeficiency virus), or has severe autoimmune disease that
             requires chronic immunosuppressive therapy (e.g., systemic lupus erythematosus, etc.)
             The patient should also not receive inhibitors of CYP3A (such as Itraconazole, and
             Erythromycin), or inducers of CYP3A (such as Rifampin) within 90 days following the
             procedure.

          -  Subject is receiving or is scheduled to receive chronic anticoagulation therapy (e.g.,
             heparin, coumadin)

          -  Use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation
             therapy) as part of the index procedure</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Prince of Wales Hospital - Sydney</hospital>
    <hospital>Epworth Hospital - Melbourne</hospital>
    <postcode>2031 - Sydney</postcode>
    <postcode>3121 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Delft</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The University of New South Wales</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>ABSORB BTK Study: A prospective, multicenter, controlled clinical evaluation of the use of a
      bioresorbable drug eluting stent in the arterial vasculature below the knee</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02793349</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ramon L Varcoe, MS,FRACS,PhD</name>
      <address>Prince of Wales Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Ramon L Varcoe, MS,FRACS,PhD</name>
      <address />
      <phone>+6129650 4947</phone>
      <fax />
      <email>r.varcoe@unsw.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>